This study is a single-arm, open-label, multicenter phase 2 trial designed to prospectively evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab for mismatch repair proficient recurrent endometrial cancer in Black patients (a population under-represented on 2 FDA registration trials).
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants compared to the efficacy reported in the historical trials leading to US FDA approval of the regimen